Clinicians should be aware of atypical presentations of haemorrhage, such as massive subcutaneous chest wall haemorrhage, when using combination antiplatelet and antithrombotic therapy including enoxaparin.
May prompt vigilance for atypical enoxaparin-related bleeding; case report leaves open incidence and causality.
Enoxaparin is used in the treatment of acute coronary syndromes and offers improved outcome in the composite endpoint of death, myocardial infarction and major bleeding when compared with unfractionated heparin (UFH). Our report describes a rare case of massive life-threatening subcutaneous chest wall haemorrhage, distant to the injection site. Clinicians should be aware of atypical presentations of haemorrhage when using combination antiplatelet and antithrombotic therapy.
No takes yet. Share an insight, caveat, or question.
Rahman et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: